UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Linge J
(2018)
Body Composition Profiling in the UK Biobank Imaging Study.
in Obesity (Silver Spring, Md.)
Panter J
(2018)
Using alternatives to the car and risk of all-cause, cardiovascular and cancer mortality.
in Heart (British Cardiac Society)
Gilbert K
(2019)
Independent Left Ventricular Morphometric Atlases Show Consistent Relationships with Cardiovascular Risk Factors: A UK Biobank Study.
in Scientific reports
Bovijn J
(2019)
GWAS Identifies Risk Locus for Erectile Dysfunction and Implicates Hypothalamic Neurobiology and Diabetes in Etiology.
in American journal of human genetics
Hwang LD
(2019)
New insight into human sweet taste: a genome-wide association study of the perception and intake of sweet substances.
in The American journal of clinical nutrition
Ge T
(2019)
The Shared Genetic Basis of Educational Attainment and Cerebral Cortical Morphology.
in Cerebral cortex (New York, N.Y. : 1991)
Sallis HM
(2019)
Cigarette smoking and personality: interrogating causality using Mendelian randomisation.
in Psychological medicine
Nakka P
(2019)
Characterization of Prevalence and Health Consequences of Uniparental Disomy in Four Million Individuals from the General Population.
in American journal of human genetics
Teumer A
(2019)
Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria.
in Nature communications
Beesley L
(2019)
The emerging landscape of health research based on biobanks linked to electronic health records: Existing resources, statistical challenges, and potential opportunities
in Statistics in Medicine
Slade GD
(2019)
Anatomical selectivity in overlap of chronic facial and bodily pain.
in Pain reports
Meng W
(2019)
Genome-wide association study of knee pain identifies associations with GDF5 and COL27A1 in UK Biobank.
in Communications biology
Mollink J
(2019)
The spatial correspondence and genetic influence of interhemispheric connectivity with white matter microstructure.
in Nature neuroscience
Gregson J
(2019)
Cardiovascular Risk Factors Associated With Venous Thromboembolism.
in JAMA cardiology
Grueneberg A
(2019)
BGData - A Suite of R Packages for Genomic Analysis with Big Data.
in G3 (Bethesda, Md.)
Olivo G
(2019)
Low neuroticism and cognitive performance are differently associated to overweight and obesity: A cross-sectional and longitudinal UK Biobank study.
in Psychoneuroendocrinology
Garske KM
(2019)
Reverse gene-environment interaction approach to identify variants influencing body-mass index in humans.
in Nature metabolism
Crawford K
(2019)
Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank.
in Journal of medical genetics
Fries JA
(2019)
Weakly supervised classification of aortic valve malformations using unlabeled cardiac MRI sequences.
in Nature communications
Pilling LC
(2019)
Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank.
in BMJ (Clinical research ed.)
Mullins N
(2019)
GWAS of Suicide Attempt in Psychiatric Disorders and Association With Major Depression Polygenic Risk Scores.
in The American journal of psychiatry
Rask-Andersen M
(2019)
Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects.
in Nature communications
Van Der Plaat DA
(2019)
Age at menopause and lung function: a Mendelian randomisation study.
in The European respiratory journal
Batty GD
(2019)
Assessment of Relative Utility of Underlying vs Contributory Causes of Death.
in JAMA network open
Wang H
(2019)
Genome-wide association analysis of self-reported daytime sleepiness identifies 42 loci that suggest biological subtypes.
in Nature communications
Hindy G
(2019)
Cardiometabolic Polygenic Risk Scores and Osteoarthritis Outcomes: A Mendelian Randomization Study Using Data From the Malmö Diet and Cancer Study and the UK Biobank.
in Arthritis & rheumatology (Hoboken, N.J.)
Lipunova N
(2019)
External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank.
in Frontiers in oncology
Thompson WD
(2019)
Association of maternal circulating 25(OH)D and calcium with birth weight: A mendelian randomisation analysis.
in PLoS medicine
Dixon P
(2019)
The Association Between Adiposity and Inpatient Hospital Costs in the UK Biobank Cohort.
in Applied health economics and health policy
Klarin D
(2019)
Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.
in Nature genetics
Pierson E
(2019)
Inferring Multidimensional Rates of Aging from Cross-Sectional Data.
in Proceedings of machine learning research
Carter JL
(2019)
Reproducibility of dietary intakes of macronutrients, specific food groups, and dietary patterns in 211 050 adults in the UK Biobank study.
in Journal of nutritional science
Riegel B
(2019)
Shift Workers Have Higher Blood Pressure Medicine Use, But Only When They Are Short Sleepers: A Longitudinal UK Biobank Study.
in Journal of the American Heart Association
Clark DW
(2019)
Associations of autozygosity with a broad range of human phenotypes.
in Nature communications
Aguirre M
(2019)
Phenome-wide Burden of Copy-Number Variation in the UK Biobank.
in American journal of human genetics
Suzuki H
(2019)
Associations of Regional Brain Structural Differences With Aging, Modifiable Risk Factors for Dementia, and Cognitive Performance.
in JAMA network open
Wills AG
(2019)
Phenotypic and genetic relationship between BMI and cigarette smoking in a sample of UK adults.
in Addictive behaviors
Pazoki R
(2019)
GWAS for urinary sodium and potassium excretion highlights pathways shared with cardiovascular traits.
in Nature communications
Pulit SL
(2019)
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
in Human molecular genetics
Cox SR
(2019)
Structural brain imaging correlates of general intelligence in UK Biobank.
in Intelligence
Zenin A
(2019)
Identification of 12 genetic loci associated with human healthspan.
in Communications biology
Nazarzadeh M
(2019)
Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study.
in JAMA cardiology
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |